mark voskoboynik

When you firebomb a synagogue with people inside & attack a local restaurant because it’s owned by Jews, it’s NOT about Israel, it’s NOT about protest, it’s a hate crime. Violent antisemitism is a threat to us all & until it’s called out for what it really is, it will continue!

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects 🔥Hot off the press @TheLancetOncol: thelancet.com/journals/lanon… 💊Lu-PSMA followed by docetaxel vs. docetaxel alone (130 men randomised) 🎯Undetectable PSA at 1 year: 41% vs 16% (OR 3·88; p=0·0020) 💥No additional side effects with Lu-PSMA ✅Secondary endpoints favour Lu-PSMA as well 🎥Watch it on GU Cast: youtu.be/S_JvSVlOdZ8 Investigator-led study @AzadOncology @PeterMacCC Big shout out to @MovemberAUS and all other funders & supporters @CDMRP @UniMelb #VCA #MRFF @ANSTO @Novartis @pros_tic Thanks to @ANZUPtrials #ARTnet 👏UprontPSMA Study Team all around Australia

(1/3) ALPN-202 (davo) is a novel agent that inhibited PD-1/CTLA-4 with PD-L1-dependent CD28 co-stim. Dose-escalated singly (NEON-1) & with pembro (NEON-2). Dose-dependent PK both as mono and combo with moderate ADA incidence (14% vs. 24%). jitc.bmj.com/content/12/8/e…

Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors @jitcancer @diwakardavar @LudiCa19862 @_vosko @RachelSanbornMD @JustinGainor #Cancer #OncoDaily #Oncology #CancerCare #CancerResearch oncodaily.com/119169.html

ENZA-P in @TheLancetOncol Lu-177 PSMA-617 + enzalutamide vs. enza alone: ● ↑PFS: 13.0 vs 7.8, hazard radio 0.43 ● PSA90 response 78% vs 37% ● PSA50 response 93% vs. 68% ● no additional side effects Incredible work from @drlouiseemmett @Prof_IanD & @ANZUPtrials team #ArtNet authors.elsevier.com/c/1iw3e5EIIgPd… Thanks @MovemberAUS @Novartis for funding

ENZA-p trial @TheLancetOncol authors.elsevier.com/a/1iw3e5EIIgPd… Enzalutamide + adaptive-dosed (2 or 4) 177 Lu-PSMA617 vs enza alone in mCRPC. Biomarker guided combination therapy works! Better response depth/duration with no added tox. @ANZUPtrials @TrialsCentre @MovemberAUS @SVHSydney

The @myESMO leadership course is one of the best things I’ve done 🌏 Focussing on oncology issues for Asia-Pacific region 👥 Comms/leadership skills 🤩 Connecting with new colleagues/friends/ESMO mentors Apply now 👇

Highlighting the need for better #diversity in #ClinicalTrials and the need to provide these services where people actually live. @EHCSMonash @easternhealthau @Monash_FMNHS @ACTA_org @theheraldsun

Feeling young after being able to snap 📸 a #Wefie with graduates of @myESMO Asia #LGP programme. Thanks mentors including @ravikanesvaran for mentoring a new generation of oncology leaders in our region! @anmwongNZ @PoonEileen @reswong #mentorship #ESMOAsia22

So exciting to see this new work published on immunotherapy impacts to fertility @NatureCancer. This research strongly advocates we must include reproductive endpoints in clinical trials moving forward! nature.com/articles/s4301…

162/162 randomised on the ENZAp trial. Primary endpoint PSA-PFS enzalutamide vs enzalutamide + Lu PSMA-617. Huge translational side. Matched serial PSMA (FDG) PET, SPECT, RECIST, CTC, ctDNA - prognostic, predictive and interim response biomarkers. Thx everyone involved!

🥁Thrilled to announce that our paper is out @NatureMedicine! We looked at the impact of nivolumab/ipilimumab +/- #CBM588 a bifidogenic live bacterial product, on gut #Microbiome, serum cytokines & clinical outcomes in #mRCC 🙏🙏@montypal @LuisMezaco @PauloBergerot et al. 1/n🧵

It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021: Some negative, some positive, some led to @FDAOncology approval; we learned from all! Feel free to add & retweet & tag anyone involved This is not an exhaustive list @OncoAlert

Just out in Annals of Oncology, results of the first-in-human phase 1 study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab. The patient population included anti–PD-1/PD-L1‒refractory NSCLC 🫁 annalsofoncology.org/article/S0923-…

LATE PHASE 1 STUDY. A new highly needed design. thelancet.com/journals/lanon… @GustaveRoussy @JcbenitezMD @ArthurGeraud @drcmassard @jsoriamd

@TommyJohn00 @IASLC @StephenVLiu great interview Tom! Excellent message. As oncologists, for our patients we sometimes have to help find the clarity in the mayhem but we mustn’t forget to look after ourselves 😉

@IASLC @StephenVLiu Listening to this, I realise what an amazing psychoanalyst Stephen is! Thanks again for the invitation. I hope it helps people talk about not just career paths but also #burnout and focusing on other things beyond career.

In this edition of #LungCancerConsidered, host @StephenVLiu talks with physician-researcher and musician Dr. Thomas John. @TommyJohn00, performing as Mayhemtom shares his new single ‘Reach Out’. linktr.ee/mayhemtom You can listen to the podcast here: ow.ly/twid50FA2he

Cancer patients in Gippsland will have better access to clinical trials locally thanks to a partnership between Alfred Health’s Trialhub and Latrobe Regional Hospital. More: bit.ly/3tEirga

Congrats to @_vosko & team @AlfredHealth for randomising 1st 2 pts on #UpFrontPSMA! A first-in-field study of #LuPSMA in mHS #ProstateCancer. Thx to funders (@MovemberAUS , MRFF, DoD) and especially patients & families. clinicaltrials.gov/ct2/show/NCT04…

Dr. Mark Voskobynik @_vosko will be presenting a Trials In Progress poster at #AACR21 on ALPN-202, our first-in-class conditional CD28 costimulator/dual PD-L1/CTLA-4 inhibitor. Learn more about the NEON-1 trial for patients with #cancer. More details: ir.alpineimmunesciences.com/news-releases/…

It's Monday AM post-@ASCO #GU21 & clinic starts in a couple of hours! Lots to process - I'll try to tackle optimal 1L tx for #kidneycancer. I'll make a case for cabo/nivo, leaning on the beautiful (& timely) tables below from @lalaniMD, @SoaresAndrey & @brian_rini (1/15)